Payment overview · 2025
General Payments
$3,614.61
184 reported records · 22 companies
Healthcare provider profile · identity verified
Jarod E Speer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHILDERSBURG, AL · NPI 1609947993
Verified facts
What the public records show
CMS Open Payments records show Jarod E Speer, M.D. received $3,614.61 in general payments during 2025 across 184 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 443 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $434.66 | 12.0% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $430.02 | 11.9% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $414.39 | 11.5% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $377.17 | 10.4% | 26 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $257.48 | 7.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $247.72 | 6.8% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $196.14 | 5.4% | 10 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $196.03 | 5.4% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $174.41 | 4.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.39 | 3.9% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $130.58 | 3.6% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $105.34 | 2.9% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $79.43 | 2.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.23 | 1.8% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.82 | 1.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.17 | 1.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.05 | 1.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.36 | 1.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $42.56 | 1.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.35 | 1.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.98 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.33 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,614.61 | 184 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $434.66 | 21 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $255.95 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $249.98 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $234.09 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $218.97 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $203.40 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $196.14 | 10 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $196.03 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $190.25 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $178.70 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $174.41 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $164.41 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $147.90 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $143.08 | 11 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $142.44 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $130.58 | 7 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $115.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $111.92 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.92 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $87.64 | 5 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $79.43 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $64.23 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.82 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.05 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.38 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.55 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.36 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.70 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 114 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 113 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 160 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 121 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 443 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 254 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 168 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
121 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
84 | 66 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
168 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
443 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
254 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 864 | 248 |
| Lisinopril | Lisinopril | 665 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 212 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 634 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 599 | 181 |
| Mounjaro | Tirzepatide | 443 | 63 |
| Metformin Hcl | Metformin Hcl | 442 | 141 |
| Carvedilol | Carvedilol | 356 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 341 | 108 |
| Omeprazole | Omeprazole | 341 | 96 |
| Gabapentin | Gabapentin | 302 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 85 |
| Ozempic | Semaglutide | 254 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 248 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 242 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 69 |
| Sertraline Hcl | Sertraline Hcl | 234 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 62 |
| Trazodone Hcl | Trazodone Hcl | 201 | 68 |
| Losartan Potassium | Losartan Potassium | 179 | 60 |
| Celecoxib | Celecoxib | 174 | 68 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 168 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 168 | 43 |
| Meloxicam | Meloxicam | 163 | 61 |
| Jardiance | Empagliflozin | 160 | 42 |
| Spironolactone | Spironolactone | 149 | 44 |
| Tramadol Hcl | Tramadol Hcl | 148 | 27 |
| Clonazepam | Clonazepam | 146 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 45 |
| Glipizide | Glipizide | 135 | 44 |
| Famotidine | Famotidine | 129 | 41 |
| Alprazolam | Alprazolam | 127 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 38 |
| Atenolol | Atenolol | 122 | 39 |
| Kerendia | Finerenone | 121 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 35 |
| Eliquis | Apixaban | 114 | 37 |
| Ibuprofen | Ibuprofen | 114 | 42 |
| Farxiga | Dapagliflozin Propanediol | 113 | 27 |
| Azithromycin | Azithromycin | 110 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 35 |
| Montelukast Sodium | Montelukast Sodium | 104 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 33 |
| Alendronate Sodium | Alendronate Sodium | 92 | 28 |
| Ezetimibe | Ezetimibe | 89 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 84 | 66 |
| Furosemide | Furosemide | 82 | 28 |
| Simvastatin | Simvastatin | 81 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 24 |
| Pregabalin | Pregabalin | 74 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 20 |
| Buspirone Hcl | Buspirone Hcl | 69 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 20 |
| Allopurinol | Allopurinol | 68 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 20 |
| Amoxicillin | Amoxicillin | 63 | 54 |
| Methylprednisolone | Methylprednisolone | 63 | 55 |
| Chlorthalidone | Chlorthalidone | 59 | 19 |
| Januvia | Sitagliptin Phosphate | 59 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 56 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 16 |
| Diazepam | Diazepam | 55 | 13 |
| Linzess | Linaclotide | 55 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 18 |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 51 | suppressed |
| Levemir Flexpen | Insulin Detemir | 51 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 18 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | 16 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Valsartan | Valsartan | 44 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 40 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Topiramate | Topiramate | 39 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | 15 |
| Xarelto | Rivaroxaban | 36 | 11 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 16 |
| Fluconazole | Fluconazole | 33 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 12 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Methocarbamol | Methocarbamol | 31 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | 11 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 28 | 28 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,614.61 · 184 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error